(Q48969176)

17 February 2018

title

Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis. (English)

1 reference

17 February 2018

0 references

0 references

Roland Martin

1

1 reference

17 February 2018

publication date

1 September 2008

1 reference

17 February 2018

published in

Lancet Neurology

1 reference

17 February 2018

volume

7

1 reference

17 February 2018

issue

9

1 reference

17 February 2018

page(s)

765-766

1 reference

17 February 2018

Multiple sclerosis: a complicated picture of autoimmunity.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970174-1

7 January 2021

10.1016/S1474-4422(08)70174-1

Identifiers

DOI

1 reference

17 February 2018

1 reference

17 February 2018